Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis
Diabetes, Obesity and Metabolism · 08.11.2026
DOI: 10.1111/dom.71525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.11.2026. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of K…. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objectives
Hyperuricemia and gout are common but underappreciated comorbidities in Type 2 diabetes (T2D), obesity and chronic kidney disease (CKD). We aimed to quantify the pooled effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists on serum uric acid (SUA), incident gout and hyperuricemia, and to determine whether these effects vary by drug class and are mediated by weight loss.
Methods
We searched PubMed/MEDLINE, Embase, CENTRAL and ClinicalTrials.gov through July 2026 for RCTs of ≥ 12 weeks' duration reporting SUA change, gout flares or hyperuricemia incidence. Random‐effects meta‐analysis, subgroup and sensitivity analyses and meta‐regression were performed. Registered with PROSPERO (CRD420261468511).
Results
Eighteen RCTs (77 942 participants) met inclusion criteria. Incretin‐based therapy significantly reduced SUA versus control (weighted mean difference [WMD] −0.44 mg/dL, 95% CI −0.52 to −0.35), reduced incident gout flares (hazard ratio [HR] 0.62, 95% CI 0.53–0.72), and reduced hyperuricemia incidence (odds ratio [OR] 0.61, 95% CI 0.53–0.70). Dual GIP/GLP‐1 RA (tirzepatide) produced greater SUA lowering than mono GLP‐1 RAs (−0.62 vs. −0.35 mg/dL, p = 0.001). Body‐weight loss was a significant moderator of SUA reduction ( β = −0.041 mg/dL per kg, p < 0.001), explaining 84.7% of between‐trial heterogeneity, with a significant weight‐independent intercept (−0.19 mg/dL, p < 0.001). The SUA reduction was robust in all sensitivity analyses, including restriction to placebo‐controlled trials. GRADE certainty was high for SUA and moderate for gout flares (owing to small‐study effects) and hyperuricemia incidence.
Conclusion
Incretin‐based therapies were associated with modest reductions in SUA and with a lower incidence of gout flares and hyperuricemia, an effect largely related to weight loss. The clinical relevance of these effects, and the mechanism of any weight‐independent component, remains uncertain and warrant confirmation in dedicated trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Young Ho Lee
Zitieren
APA
Lee, Y. H., & Song, G. G. (2026). Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71525
Vancouver
Lee YH, Song GG. Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71525
BibTeX
@article{Lee2026,
author = {Lee, Young Ho and Song, Gwan Gyu},
title = {Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71525}
}
EUVIMED